And a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt to discredit it, tar and feather it, and convince you not to watch it. That’s because it tells the shocking truth about the current AI mania… and why investors in big tech companies like Nvidia, Meta, Alphabet, and Microsoft could be in for a whole world of pain.

COEP Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 21.49%

Insider Buying (Last 12 Months): $36,841.92

Insider Selling (Last 12 Months): $0.00

Coeptis Therapeutics Insider Trading History Chart

Coeptis Therapeutics Share Price & Price History

^$0.20

+0.30 (1.20%)

As of 11/5/2024 01:00 AM ET

Days: 30 | 90 | 365

Elon knows the truth, which is why they want him silenced

From Porter & Company | Ad

Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration.

Watch this new documentary and you’ll discover what Elon knows,

Coeptis Therapeutics Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/12/2024	Tara Desilva	Director	Buy	2,266	$0.58	$1,314.28	32,266
1/10/2024	Brian Cogley	CFO	Buy	5,000	$0.67	$3,350.00	30,000
1/8/2024	David Mehalick	CEO	Buy	20,004	$0.66	$13,202.64	2,782,615
1/5/2024	Daniel Alexander Yerace	VP	Buy	10,850	$0.69	$7,486.50	1,071,455
1/5/2024	David Mehalick	CEO	Buy	5,050	$0.69	$3,484.50	2,762,611
1/5/2024	Gene Salkind	Director	Buy	11,600	$0.69	$8,004.00	284,056
8/29/2023	Gene Salkind	Director	Buy	4,006	$1.01	$4,046.06	4,046
8/25/2023	Gene Salkind	Director	Buy	28,638	$0.91	$26,060.58	28,638
8/23/2023	Chris Calise	Director	Buy	11,582	$0.94	$10,887.08	1,464,897

Bill Gates’s Next Big AI Bet: Stargate

From Brownstone Research | Ad

In February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of my favorite stocks. Shares have jumped by more than 20,000% since then.

I believe we are about to do it again with this new AI project called Stargate

SEC Filings (Institutional Ownership Changes) for Coeptis Therapeutics (NASDAQ:COEP)

13.88% of Coeptis Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Coeptis Therapeutics Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
2/13/2024	Armistice Capital LLC	3,520,000	$2.76M	0.0%	+59.1%	10.320%
11/15/2023	Armistice Capital LLC	2,212,000	$2.57M	0.0%	-5.1%	8.799%
8/15/2023	Ionic Capital Management LLC	45,000	$70K	0.0%	N/A	0.209%
7/21/2023	Creative Planning	645,103	$1M	0.0%	N/A	2.995%
5/12/2023	Antara Capital LP	45,000	$64K	0.0%	N/A	0.220%
2/14/2023	Susquehanna International Group LLP	16,341	$25K	0.0%	N/A	0.319%
2/10/2023	Creative Planning	645,103	$0.99M	0.0%	N/A	12.600%
2/10/2023	HRT Financial LP	172,635	$0.27M	0.0%	N/A	3.372%
2/8/2023	Cambridge Investment Research Advisors Inc.	31,670	$48K	0.0%	N/A	0.619%
2/6/2023	West Chester Capital Advisors Inc.	2,863,382	$4.39M	8.7%	N/A	55.925%

Data available starting January 2016

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Today's Range

Now: $0.20

$0.20

$0.21

50 Day Range

MA: $0.19

$0.16

$0.23

52 Week Range

Now: $0.20

$0.15

$1.33

Volume

96,230 shs

Average Volume

317,477 shs

Market Capitalization

$7.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Coeptis Therapeutics?: Coeptis Therapeutics' top insider investors include:
David Mehalick (CEO)
Chris Calise (Director)
Daniel Alexander Yerace (VP)
Gene Salkind (Director)
Tara Desilva (Director)
Brian Cogley (CFO)
Learn More about top insider investors at Coeptis Therapeutics.

The Final Frontier